Precision Biosensor, Inc.

As of June 30, 2026, Precision Biosensor, Inc. carries a market capitalization of 33.14B, placing it among publicly traded companies globally. Its enterprise value stands at 37.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Precision Biosensor, Inc. has 21.88M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.10, and the price-to-book ratio stands at 0.79.

As of June 30, 2026, Precision Biosensor, Inc. trades at an EV/EBITDA multiple of 161.49 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 37.35B versus a market cap of 33.14B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Precision Biosensor, Inc. maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 30.64, indicating elevated leverage, while an interest coverage ratio of 0.14 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Precision Biosensor, Inc. posted a negative return on equity (ROE) of -20.16, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.57, reflecting losses generated across the asset base. The company generates approximately 244.50M in revenue per employee across its workforce of 96.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.69 indicates how many times Precision Biosensor, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Precision Biosensor, Inc. recorded 15.36M in income tax expense. The company reported a pretax loss of -6.34B and -6.35B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Precision Biosensor, Inc.'s stock has declined approximately 50.87% over the past 52 weeks. The 50-day moving average sits at 1,493.46, while the 200-day moving average is 1,946.30.

Over the twelve months ended June 30, 2026, Precision Biosensor, Inc. generated 23.66B in revenue and converted that into -6.35B in net income, yielding earnings per share of -369.26. EBITDA reached 231.27M, while operating income came in at -3.62B.

As of June 30, 2026, Precision Biosensor, Inc. holds 8.68B in cash and equivalents against 12.88B in total debt, resulting in a net debt position of 10.35B. Total book value stands at 42.05B, with working capital of 7.65B providing operational flexibility.

Precision Biosensor, Inc. produced -1.12B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -295.75M in capital expenditures, free cash flow totaled -1.42B - equivalent to -82.40 per share.

Over the twelve months ended June 30, 2026, Precision Biosensor, Inc. posted a gross margin of 37.43, reflecting its pricing power and cost economics. The operating margin of -15.29 and net profit margin of -26.85 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.44: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.84, meaning Precision Biosensor, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Precision Biosensor, Inc. has an Altman Z-Score of 0.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.